Heart failure remains significant cause of m morbidity and mortality in patients with heart failure in developed countries. Pharmacotherapy is based on the use of angiotensin converting enzyme inhibitors, beta blockers, mineralocorticoid receptor antagonists and diuretics.
Dual neprilisine and angiotensin receptor blockade represents a new modality with improvement of survival of the patients.